Table 3. Univariate and Multivariate Hazard Ratio and 95% CI for Association of Postoperative Survival (Cancer Death).
| Survive (n = 100) | Death (n = 18) | Univariate HR (95% CI) | P-value | Multivariate HR (95% CI) | P-value | |
|---|---|---|---|---|---|---|
| Age (years) | ||||||
| < 75 | 70 | 7 | 1 | 1 | ||
| ≥ 75 | 30 | 11 | 3.90 (1.51 - 10.09) | 0.005 | 2.35 (0.84 - 6.59) | 0.104 |
| Sex | ||||||
| Female | 32 | 6 | 1 | |||
| Male | 68 | 12 | 0.83 (0.31 - 2.21) | 0.706 | ||
| Stage | ||||||
| Stage I-II | 66 | 7 | 1 | |||
| Stage III | 32 | 10 | 2.54 (0.96 - 6.67) | 0.059 | ||
| Failure: 3 | ||||||
| Disease | ||||||
| Colorectal cancer | 68 | 12 | 1 | |||
| Stomach cancer | 32 | 6 | 1.13 (0.42 - 3.00) | 0.813 | ||
| Charlson comorbidity index (points) | ||||||
| ≤ 2 | 91 | 15 | 1 | |||
| > 3 | 9 | 3 | 1.98 (0.57 - 6.87) | 0.280 | ||
| Histological type | ||||||
| Undifferentiated | 8 | 3 | 1 | |||
| Differentiated | 92 | 15 | 0.43 (0.13 - 1.50) | 0.187 | ||
| CEA (ng/mL) | ||||||
| < 6 | 62 | 8 | 1 | |||
| ≥ 6 | 35 | 9 | 2.62 (1.00 - 6.85) | 0.050 | ||
| Failure: 4 | ||||||
| CA19-9 (U/mL) | ||||||
| < 37 | 81 | 14 | 1 | |||
| ≥ 37 | 12 | 3 | 1.36 (0.39 - 4.73) | 0.631 | ||
| Failure: 8 | ||||||
| CRP (mg/dL) | ||||||
| < 0.2 | 42 | 7 | 1 | |||
| ≥ 0.2 | 45 | 8 | 1.05 (0.38 - 2.91) | 0.922 | ||
| Failure: 16 | ||||||
| Albumin (g/dL) | ||||||
| ≥ 3.5 | 61 | 7 | 1 | 1 | ||
| < 3.5 | 26 | 9 | 3.22 (1.20 - 8.67) | 0.021 | 2.83 (1.03 - 7.75) | 0.043 |
| Failure: 15 | ||||||
| Hemoglobin (g/dL) | ||||||
| ≥ male 11; female 10 | 67 | 10 | 1 | |||
| < male 11; female 10 | 22 | 6 | 2.90 (1.04 - 8.09) | 0.043 | ||
| Failure: 13 | ||||||
| HbA1c (%) | ||||||
| < 6.5 | 61 | 11 | 1 | |||
| ≥ 6.5 | 15 | 3 | 0.78 (0.22 - 2.81) | 0.707 | ||
| Failure: 28 | ||||||
| PNI (points) | ||||||
| ≥ 40 | 66 | 12 | 1 | |||
| < 40 | 17 | 3 | 1.47 (0.41 - 5.21) | 0.555 | ||
| Failure: 20 | ||||||
| BMI (kg/m2) | ||||||
| 18.5 - 24.9 | 67 | 12 | 1 | |||
| < 18.5 | 17 | 4 | 1.33 (0.43 - 4.13) | 0.622 | ||
| ≥ 25 | 16 | 2 | 0.65 (0.15 - 2.91) | 0.575 | ||
| P for trend 0.403 | ||||||
| SMI (kg/m2) | ||||||
| ≥ male 6.25; female 5.17 | 80 | 10 | 1 | 1 | ||
| < male 6.25; female 5.17 | 20 | 8 | 3.07 (1.21 - 7.78) | 0.018 | 3.34 (1.21 - 9.17) | 0.020 |
| VFA (cm2) | ||||||
| ≥ 100 cm2 | 47 | 8 | 1 | |||
| < 100 cm2 | 48 | 10 | 1.16 (0.46 - 2.95) | 0.752 | ||
| Failure: 5 | ||||||
| Body fat (%) | ||||||
| ≥ male 30; female 42 | 12 | 2 | 1 | |||
| < male 30; female 42 | 88 | 16 | 0.98 (0.22 - 4.24) | 0.973 | ||
| Treatment technique | ||||||
| Laparoscopic | 21 | 0 | ||||
| Laparotomy | 79 | 18 | ||||
| Chemotherapy | ||||||
| Absence | 65 | 10 | 1 | |||
| Prescription | 35 | 8 | 1.40 (0.55 - 3.55) | 0.477 |
PNI: prognostic nutritional index; CEA: carcinoembryonic antigen; CA19-9: carbohydrate antigen 19-9; CRP: C-reactive protein; VFA: visceral fat area; BMI: body mass index; SMI: skeletal muscle mass index. Multivariate model included age, albumin and SMI.